Bundas24 Bundas24
Rezultatele cautarii
Vedeti tot
  • Conecteaza-te
    Conecteaza-te
    Inscrie-te
    Căutare
    Night Mode

Căutare

Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni

  • News Feed
  • EXPLORE
  • Pagini
  • Grupuri
  • Events
  • Blogs
  • Marketplace
  • Funding
  • Offers
  • Jobs
  • Courses
  • Forums
  • Postari
  • Blogs
  • Utilizatori
  • Pagini
  • Grupuri
  • Events
  • Kislay Kumar a adăugat un sunet Alte
    2025-05-19 13:49:52 -
    Advanced Non-Squamous and Squamous NSCLC Market is driven by immunotherapy adoption
    The Advanced Non-Squamous and Squamous NSCLC Market encompasses a broad portfolio of targeted therapies, immune checkpoint inhibitors, and next-generation diagnostics designed to improve patient outcomes in both histological subtypes of non-small cell lung cancer. Products such as PD-1/PD-L1 inhibitors, EGFR tyrosine kinase inhibitors, and novel bispecific antibodies help address treatment...
    0 Commentarii 0 Distribuiri 271 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
  • Vaibhav Gaikwad a adăugat un sunet Alte
    2025-04-17 14:48:25 -
    Non-Small Cell Lung Cancer (NSCLC) Market: Transforming Treatment Paradigms
    Non-Small Cell Lung Cancer (NSCLC) Market: Transforming Treatment Paradigms Market Overview The global NSCLC therapeutics market is projected to grow from 18.2billionin2023to18.2billionin2023to32.7 billion by 2030, at a 8.9% CAGR, driven by precision medicine advancements and increasing incidence rates. NSCLC accounts for 85% of all lung cancer cases,...
    0 Commentarii 0 Distribuiri 425 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
  • Khushbu Coherent a adăugat un sunet Health
    2025-05-20 09:22:39 -
    EGFR Non-Small Cell Lung Cancer Market Fueled by Targeted Therapies
    The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market encompasses a range of targeted therapies, companion diagnostics, and supportive care products designed to improve treatment outcomes for patients with EGFR-mutated lung tumors. Key products include first-, second-, and third-generation tyrosine kinase inhibitors (TKIs) that block aberrant EGFR signaling pathways, thereby reducing tumor...
    0 Commentarii 0 Distribuiri 189 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
© 2025 Bundas24 Romaian
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Termeni Confidențialitate Contacteaza-ne Director